PDCD1 and neoplasm: Anti-PD-1 treatments that are tumor-agnostic have been authorized based on the molecular characteristics of tumors, such as those with a high burden of non-synonymous mutations, as shown by microsatellite instability-high colorectal and endometrial malignancies (95).